VigorMeds review
Taking it under the tongue costs less here than taking it by injection.
The verdict
VigorMeds charges $199 a month for semaglutide by weekly injection and $139 for the sublingual, and the gap on tirzepatide is wider still at $299 against $159, which makes the needle the expensive choice on both molecules. The customer reviews propping up those pages are worth weighing carefully, because all twelve on the semaglutide injection page carry the same month and the same count of people who found them helpful.
Disclosure: This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. How we make money.
- Category
- GLP-1 telehealth
- Molecule
- Semaglutide · Tirzepatide
- Form
- Injection · Oral
- Injection
- From $199/mo
- Oral
- From $139/mo
- Dose published
- No
- Prescription
- Required
- Compounded
- Yes — not FDA-approved
- Pharmacy
- Not named
VigorMeds is a telehealth catalog whose weight-management line sells compounded semaglutide and compounded tirzepatide as weekly injections and as daily sublinguals, with microdosing versions of both, liraglutide and a naltrexone combination listed as coming soon. Anti-aging, hair loss and erectile dysfunction programs sit in the same storefront.
Who writes the prescription, and what do they see?
The site describes the medication as dispensed following professional review and according to established medical standards, which is a sentence about process rather than about a person. No prescriber, medical group or medical director is named anywhere on the product pages. Nothing published describes what a clinician looks at before approving a plan, or how long that takes.
Each product is sold as a one-month or a three-month plan, and the product page arrives with the one-month plan already chosen rather than the longer one, which is the less common way around. A site-wide promotional code takes a fixed amount off, and because it is a first-order discount the standing figure is what a patient keeps paying. An interactive estimator on the page turns a current weight into a projected loss under three different assumptions.
What happens when the dose goes up?
Nothing on the product page states what happens to the price as the dose climbs, and no milligram figure appears beside the entry rate for either molecule. Every rate is written as a starting figure rather than a ceiling, which leaves the step up unpriced. Microdosing versions are sold as separate products rather than as a rung on the same ladder.
What the price includes
Semaglutide is $199 injected and $139 sublingual; tirzepatide is $299 injected and $159 sublingual, so the non-injectable route saves $60 on one molecule and $140 on the other. The product page confirms the entry figure as a one-month plan rather than a prepaid term, which is worth knowing before comparing it with sellers whose headline is a year. The promotional code applies to a first order only.
What it claims, and what it cites
Both molecules are sold in compounded form, prepared to order by a pharmacy rather than manufactured, which means the FDA does not review the preparation before it is dispensed. No compounding pharmacy is named on the product pages. No LegitScript certification is claimed.
Where it holds up, and where it does not
- Strength: The sublingual costs less than the injection on both molecules
- Strength: The product page defaults to a one-month plan
- Strength: Four format prices are published in one grid
- Strength: Microdosing versions are priced separately and openly
- Strength: A projected-loss estimator is offered in three modes
- Limitation: Every testimonial carries the same date and helpful count
- Limitation: No prescriber or medical group is named
- Limitation: No compounding pharmacy is named
- Limitation: Each rate is a starting figure with no dose attached
What the evidence says about this kind of treatment
The assessment above is about VigorMeds. These are about the drugs it sells, and they are traced to the primary literature.
- Right for
- A buyer who would rather take a daily sublingual than a weekly injection.
- Wrong for
- A buyer who weighs a seller by the testimonials on its product pages.
How VigorMeds compares
| Seller | Who it suits | Go |
|---|---|---|
| A reader comparing a monthly rate against a prepaid block, because this seller publishes both for the same product. | See Breeze Meds → | |
| A reader starting on a low dose, which is the tier these advertised rates are quoted against. | See CoreAge Rx → | |
| A reader willing to read the terms of service before the checkout total, because the low rate and the listed rate are different numbers. | See Embody → |
More GLP-1 telehealth sellers reviews: Live VitalLiveaLongevixxLttlLuciLuma Meds
Sponsored alternative
Bodybuilding Health+
Readers who want to start without committing a year of money
Check Bodybuilding Health+ availability →Frequently asked
- Is the sublingual really cheaper than the shot?
- Yes, on both molecules. Semaglutide is $139 against $199, and tirzepatide is $159 against $299.
- Is the entry price a prepaid term?
- No. The semaglutide product page shows the one-month plan selected at the same figure the catalog card quotes.
- What should I make of the reviews?
- Weigh them carefully. All twelve on the semaglutide injection page share one month and one identical count of helpful votes.
- Is VigorMeds expensive compared with other GLP-1 telehealth sellers?
- VigorMeds publishes a starting figure of $139/mo. Across the 225 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $76 to $399 with a median of $179, which puts VigorMeds below the median, toward the cheaper end. The other 18 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes.